Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START trial of darolutamide versus capecitabine in androgen receptor-positive triple-negative advanced breast cancer
2024-516638-36-00Phase 2Completed
- Sponsor
- Unicancer
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Darolutamide arm with Capecitabine arm (2 arms). Primary endpoint: Clinical benefit rate at 16 weeks. Started Mar 2018; status: completed.
02
Drugs
darolutamidecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516638-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516638-36-00.